Lifecore Biomedical Inc Stock Price, News & Analysis

Lifecore Biomedical has announced the successful sale of its O Olive Oil and Vinegar business for $6.23 million, marking the completion of its monetization of remaining Curation Foods assets. The deal includes $3.12 million in cash and a $3.12 million seller's note maturing on March 31, 2026, accruing 12% interest. The O Olive business generated $9.2 million in revenue over the trailing twelve months ending November 27, 2022. Proceeds from the sale will be used to repay existing borrowings under credit facilities, and results from O Olive will be reported as discontinued operations starting fiscal Q4 2023. CEO James G. Hall emphasized the company's focus on long-term growth strategies to meet customer demand.

Lifecore Biomedical has announced a new term sheet to expand its relationship with a long-term customer in the Hyaluronic Acid sector. The agreement includes a non-refundable cash commitment of $10 million from the customer, divided into installments over seven months, to enhance Lifecore's infrastructure and manufacturing capacity. Additionally, the customer aims to reimburse Lifecore up to $15 million for capital expenditures related to this expansion. This could lead to a multi-year amendment of the existing contract manufacturing agreement, enhancing Lifecore's operational capabilities and financial efficiency.

Lifecore Biomedical, based in Chaska, Minnesota, announced on March 16, 2023, that its Board of Directors will evaluate strategic alternatives to maximize shareholder value. These alternatives could include a potential sale of the Company and financing transactions. Morgan Stanley has been appointed as the financial advisor, and Latham & Watkins as legal counsel. The strategic review will begin once Lifecore secures a forbearance agreement from its lenders. CEO James G. Hall emphasized the company’s commitment to its customers and employees and highlighted the growing demand for specialized contract development and manufacturing services.

Lifecore Biomedical announced its intention to explore strategic alternatives, including a potential sale, to maximize shareholder value. The company reported fiscal second quarter 2023 results showing consolidated revenues of $38.8 million, down 10.7% year-over-year, and a consolidated net loss of $12.4 million. Gross profit decreased by 51.7% to $7.1 million. Lifecore's development pipeline expanded to 25 active projects, and it entered a term sheet to expand its relationship with a key customer, involving substantial upfront payments. The company has withdrawn its fiscal 2023 guidance due to the strategic review.

Lifecore Biomedical has completed the sale of its Curation Foods avocado products business for $17.5 million in cash, with proceeds aimed at reducing debt. This sale marks a strategic move to focus on its core operations as a contract development and manufacturing organization (CDMO).

The sale involves Yucatan Foods, LLC and will be reflected as discontinued operations starting in the fiscal third quarter of 2023. Lifecore plans to use the net proceeds to pay down borrowings, thereby enhancing its financial position. The CEO expressed optimism about further monetizing remaining assets within Curation Foods.

Lifecore Biomedical announced it received a notice from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ending November 27, 2022. The company has 60 days from January 11, 2023, to submit a compliance plan, with a potential extension to July 5, 2023, if accepted. The notice does not affect the trading of Lifecore's securities. Lifecore is committed to filing the report promptly to regain compliance.

Lifecore Biomedical has successfully raised $38.75 million through a private placement of Series A convertible preferred stock to enhance its working capital and execute capital expenditures. This move coincides with the company's ongoing divestment of non-CDMO assets. Additionally, Lifecore has amended its credit facilities to boost liquidity by deferring $2.2 million in debt repayments until 2025 and relieving certain financial covenants. The company also appointed Nathaniel Calloway, PhD, and Christopher Kiper to its Board of Directors.

Lifecore Biomedical has announced a successful closing of a $5 million private placement of its common stock at $7.97 per share, with Wynnefield Capital as an investor. The funds will be utilized for capital expenditures to enhance manufacturing capacity, responding to growing demand for complex sterile injectable pharmaceuticals. President James G. Hall noted the ongoing demand for their specialized manufacturing capabilities and emphasized the importance of long-term stockholder support in achieving growth ambitions.

Lifecore Biomedical has officially completed its transition from Landec Corporation, adopting its new name and Nasdaq ticker symbol, LFCR, effective November 15, 2022. This change reflects the company's strategic focus on its contract development and manufacturing organization (CDMO) business, specializing in sterile injectable pharmaceutical products and Hyaluronic Acid. The corporate headquarters has relocated to Chaska, MN, and a new investor relations website has been launched. Leadership remains stable as the company aims for revenue and EBITDA growth.